Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with up to $1.8B in milestones.
Antares Therapeutics will be collaborating with Novartis to find unique small molecule candidates for multiple “undruggable” cancer targets, with the biotech receiving $105 million upfront.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.
On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a…
Novartis inks second molecular glue deal with Orionis Biosciences, paying $40M upfront and up to $1.4B in milestones across…
Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and…
Novartis eyes Alzheimer's and Parkinson's as it looks to expand the AOC platform acquired in its $12 billion Avidity Biosciences…
Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational…
